Vir Biotechnology Beats Estimates with $0.31 Q4 Loss

On February 23, 2026, Vir Biotechnology, Inc. (VIR) reported a fourth-quarter loss of $0.31 per share, delivering a positive surprise to the market. This figure came in well ahead of the Zacks Consensus Estimate, which had projected a wider loss of $0.42 per share. The performance suggests the company's operational and financial strategies are yielding better-than-expected results, a key factor for investor sentiment.

Loss Shrinks 59% From Prior Year

The latest quarterly results mark a significant improvement in the company's financial health compared to the previous year. The $0.31 per share loss represents a 59% reduction from the $0.76 per share loss recorded a year ago. This substantial year-over-year improvement indicates stronger operational efficiency or revenue performance, positioning the company on a more solid financial footing. The positive earnings surprise is likely to attract investor attention and could influence analyst ratings and price targets.

Vir Narrows Q4 Loss to $0.31 Per Share

Loss Shrinks 59% From Prior Year